DEPLOYDatabase

Robot model

Remebot

China's first NMPA-approved neurosurgical robot (Class III, 2018).

Track Remebot
Manufacturer
Remebot
Form factor
surgical
Maturity
production
Lifecycle
active
Deployments
1
Website
remebot.com.cn ↗

The verified answer

As of Aug 2026, DEPLOY verifies Remebot, a surgical by Remebot (production): 1 verified deployment on record. 1 source back the record.

Overview

China's first NMPA-approved neurosurgical robot (Class III, 2018). Features a six-axis robotic arm with CT/MRI-compatible visual imaging system, AI-based image identification, and 0.5mm positioning precision guided by an independent optical navigation system. Used for brain biopsy, hematoma drainage, and deep brain stimulation electrode implantation across 300+ hospitals

Verified vs. claimed

Maturity stage
production(Full-scale production deployment with repeat customers.)
Sources on file
View all sources →

Key facts

Form factor

surgical

Regulatory approval

NMPA 2018

Procedures

biopsy, hematoma drainage, DBS electrode placement

Targeting precision

sub-millimeter

Specs

Procedures

biopsy, hematoma drainage, DBS electrode placement

Clearance body

NMPA

Procedure types

biopsy, hematoma drainage, DBS electrode placement

Regulatory approval

NMPA 2018

Data & sources

Web sources

1

1 source backing this record.View all →

Pricing

No verified price is on record for Remebot. Physical-AI systems are often sold through enterprise contracts or operated as a service rather than at a public list price.

How DEPLOY tracks pricing

Deployments (1)

Free to use on your site, with a link back to DEPLOY.

Remebot on the deployment map

View the global map

Where Remebot is verified operating. Explore the deployment map by place and type.

Free to use on your site, with a link back to DEPLOY.

Recent activity

Every change to this record is dated, sourced, and independently verified where marked.

Full change history →

Safety record

No incidents on record for Remebot.

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Sources (1)

  1. Remebot Neurosurgical Robot | Beijing Baihui Weikang Technology · https://www.remebot.com.cn/

Common questions

What is Remebot?
China's first NMPA-approved neurosurgical robot (Class III, 2018). Features a six-axis robotic arm with CT/MRI-compatible visual imaging system, AI-based image identification, and 0.5mm positioning precision guided by an independent optical navigation system. Used for brain biopsy, hematoma drainage, and deep brain stimulation electrode implantation across 300+ hospitals
How much does Remebot cost?
Remebot's price is not publicly disclosed. DEPLOY has no verified price on record for Remebot from Remebot. Physical-AI systems like this are often sold through enterprise contracts or operated as a service rather than at a public list price; check the manufacturer for the latest.
Is Remebot actually deployed in the real world?
Yes. Remebot is independently verified in real-world operation on the DEPLOY registry, confirmed at named deployment sites with primary sources: not a concept, render, or demo-only.
Who makes Remebot?
Remebot is made by Remebot, based in Beijing, China, founded in 2010.
Where is Remebot deployed?
1 verified deployment of Remebot is on the DEPLOY registry, including at Beijing, China.
Can you buy Remebot?
Remebot is in commercial deployment and is sold to operators; contact the manufacturer to buy, and see the pricing section for any recorded price.
What are alternatives to Remebot?
On the DEPLOY registry, comparable surgical robots to Remebot include Edison Histotripsy System, da Vinci (and Ion), Toumai, Stryker Mako SmartRobotics.
How does Remebot compare to Edison Histotripsy System?
Remebot and Edison Histotripsy System (HistoSonics · 14 deployments) are both surgical robots on the DEPLOY registry. Remebot has 1 verified deployment on record. Compare both records for specs, safety, deployments, and verified-vs-claimed autonomy.
Is Remebot a top surgical?
On DEPLOY's intelligence score, which blends verified deployments, safety, adoption, media, and IP signals, Remebot ranks in roughly the top 77% of surgical models tracked by the registry.
What is Remebot's maturity stage?
Remebot is at the production stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Production stage means high-volume manufacture and commercial-scale deployments are sustained.
Is Remebot safe?
Remebot has no incidents on record in the DEPLOY registry. This does not constitute a safety guarantee; it reflects the incidents DEPLOY has tracked and verified to date.
Methodology: Verified · 1 source (no primary) · last reviewed 2026-08-04

Verification posture

Verified

Low confidence

Review state

Stable

Last reviewed 2026-08-04

Maturity + lifecycle

Maturity stage: production

Lifecycle: active

Architectural position

Cohort: surgical

Sources by quality tier

1
unclassified
Unclassified source

The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.

Methodology surface for Remebot.

Recent coverage

Remebot in third-party press

Remebot | Neurosurgical Robotic System Development Company of the Year in Asia 2025 - MedTech Outlook

Oct 23, 2025

Kazakhstan Takes Leap Forward with First Advanced Neurosurgical Robot in Karaganda - Caspianpost.com

Oct 20, 2025

Kazakhstan's Karaganda set to perform robotic brain surgeries - Qazinform

Oct 19, 2025